Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03356977 · ClinicalTrials.gov registry record · Phase 4
A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis
A Phase 4 study of Atopic Dermatitis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 137
- Enrollment target
- 20
- Study locations
NCT03356977 is a Phase 4 study of Atopic Dermatitis that has completed, run by Pfizer. The registered enrollment target is 137 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT03356977, a Phase 4 study of Atopic Dermatitis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 137 participants
- Enrollment target
- 20
- Study locations
Study Summary
This 4-week study will evaluate the safety, pharmacokinetics (PK), and efficacy of crisaborole ointment 2%, applied twice daily (BID) in subjects who are 3 months to less than 24 months of age with mild-to-moderate AD.
Conditions Studied
Interventions
- DRUG Crisaborole ointment 2%
Study Locations (20)
California
- Rady Children's Hospital - San Diego/University of California, San Diego - San Diego
- Rady Children's Hospital - San Diego
- University of California, San Francisco - San Francisco
Texas
- DermResearch, Inc. - Austin
- Texas Dermatology and Laser Specialists - San Antonio
Utah
- Tanner Clinic - Layton
- Jordan Valley Dermatology Center - West Jordan
Virginia
- PI-Coor Clinical Research, LLC - Burke
- Pediatric Associates of Charlottesville, PLC - Charlottesville
Arkansas
- Burke Pharmaceutical Research - Hot Springs
Colorado
- IMMUNOe Research Centers - Thornton
Florida
- Baumann Cosmetic and Research Institute - Miami
Kentucky
- DS Research - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2018-01-16 |
| Est. Completion | 2019-04-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03356977
The ClinicalTrials.gov registry entry for NCT03356977 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (78% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Crisaborole ointment 2% is the first listed.
NCT03356977 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT03356977 about?
NCT03356977 is a clinical study titled "A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis". This 4-week study will evaluate the safety, pharmacokinetics (PK), and efficacy of crisaborole ointment 2%, applied twice daily (BID) in subjects who are 3 months to less than 24 months of age with mild-to-moderate AD.
What is the current status of trial NCT03356977?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 137 participants. The study started on 2018-01-16. Estimated completion is 2019-04-12.
What conditions does trial NCT03356977 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT03356977?
The interventions under investigation include: Crisaborole ointment 2% (DRUG).
Who is sponsoring clinical trial NCT03356977?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03356977 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
-
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
RECRUITING · Phase 4
-
Molecular Signatures of Cutaneous Dupilumab Response
RECRUITING · Phase 4
-
Ethnic Differences in Mechanisms of Action of Dupilumab
RECRUITING · Phase 4
-
Dupixent and Narrowband UVB for Atopic Dermatitis
RECRUITING · Phase 4
-
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.